
27th December 2010, 11:33 AM
|
|
Member
|
|
Join Date: Nov 2007
Posts: 193
Rep Power: 7
|
|
Quote:
Originally Posted by Alchemist
Considering IPO dilution, the company will achieve an eps of around Rs 1 for FY 2010.
Assuming the IPO gets done at Rs 64/share, post-IPO the company will have Rs 30.67 per share.
Pre-IPO: 1,25,00,000 Equity shares.
Post-IPO: 2,40,00,000 Equity shares.
----------------------------------------------------
Basically, what the promoters are doing is that they are raising cash for a massive capacity expansion.
The current networth of the company is just Rs 15.25 crore.
Another 73.6 crore will be raised for the public.
This money will be used to expand the capacity from 14,25,000 cases/month to 30,00,000 cases/month and modernization of the existing plant.
If the expansion goes as planned and earnings improve, both promoters and IPO investors will benefit.
If things don't go as planned, promoters don't have much to lose - the current networth of the company is just Rs 15 crore.
The company's eps may go up to Rs 3 or Rs 4 if the expansion is completed smoothly and the extra capacity is utilized fully.
Even then the price of 64 would be considered expensive.
There is great risk and little reward in this IPO.
I am skipping this for sure.
|
Good listing for RKDL. High Risk and High Return
|